
Dr Kate Vandyke
Research Fellow (B) (with PhD)
School of Biomedicine
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
I am currently a Cancer Council SA Beat Cancer Early Career Research Fellow and co-lead of the Myeloma Research Laboratory, Faculty of Health and Medical Sciences, University of Adelaide, based at the South Australian Health and Medical Research Institute (SAHMRI), Precision Medicine Theme.
My research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma. Myeloma is the second most common blood cancer, responsible for over 100,000 deaths per year, world-wide. While significant advances in myeloma treatment over the past decade have greatly improved survival rates for multiple myeloma, almost all patients eventually relapse and succumb to their disease. My studies are primarily aimed at identifying those patients that do very poorly, surviving less than 2 years, and identifying tailored treatments for this group of patients.https://aurora.adelaide.edu.au/userprofile.html?uid=3778&em=true#
My current research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma. Myeloma is the second most common blood cancer, responsible for over 100,000 deaths per year, world-wide. While significant advances in myeloma treatment over the past decade have greatly improved survival rates for multiple myeloma, almost all patients eventually relapse and succumb to their disease. My studies are primarily aimed at identifying those patients that do very poorly, surviving less than 2 years, and identifying tailored treatments for this group of patients.
Current projects include:
- Defining major cellular and molecular mechanisms that drive tumour dissemination in multiple myeloma
- Identifying how changes to the myeloma bone marrow microenvironment drive disease progression for MGUS and smouldering myeloma to multiple myeloma
- Identification of novel serum biomarkers that enable the identification of high-risk MGUS, smouldering myeloma and multiple myeloma patients
- Using novel drug delivery strategies to increase tumour-specific drug uptake and decrease off-target side-effects in multiple myeloma
- Identification of novel therapeutic targets for the treatment of high-risk multiple myeloma
-
Appointments
Date Position Institution name 2020 - ongoing Senior research fellow South Australian Health and Medical Research Institute 2018 - ongoing Beat Cancer Early Career Research Fellow University of Adelaide, Adelaide 2017 - 2018 Post-doctoral Research Scientist University of Adelaide, Adelaide 2013 - 2016 Mary Overton Early Career Research Fellow SA Pathology 2012 - 2018 Affiliate Lecturer University of Adelaide 2012 - 2013 Multiple Myeloma Research Foundation Research Fellow SA Pathology 2010 - 2012 Post-doctoral Research Scientist SA Pathology 2007 - 2010 Technical assistant (part time) SA Pathology 2005 - 2006 Research Assistant Prince of Wales Hospital -
Education
Date Institution name Country Title 2007 - 2010 University of Adelaide Australia PhD 2000 - 2004 University of New South Wales Australia BMedSci (Hons) -
Research Interests
-
Journals
-
Conference Papers
Year Citation 2017 Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2 alpha Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2014 Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W. S., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. W. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS12013 Noll, J., Williams, S., Vandyke, K., Kok, C., & Zannettino, A. (2013). IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 GENE EXPRESSION IN A MURINE MODEL OF MYELOMA AND MYELOMA PATIENTS. In HAEMATOLOGICA Vol. 98 (pp. 316). FERRATA STORTI FOUNDATION. 2008 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel (TM)) Inhibits Oteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY. -
Conference Items
Year Citation 2019 Opperman, K., Vandyke, K., Psaltis, P., Croucher, P., Noll, J., & Zannettino, A. (2019). Macrophages as a potential therapeutic target: Clodronate-liposome treatment inhibits multiple myeloma tumour establishment in vivo. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
2019 Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Engelhardt, M., To, L. B., . . . Vandyke, K. (2019). Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
2008 Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley.
Date | Role | Grant | Funding Body | Amount |
---|---|---|---|---|
2021-2023 | CIA | Cancer Australia Priority-driven Young Investigator Grant | Cancer Australia/Cure Cancer Australia/Snowdome Foundation | AUD$198,813 |
2019-2022 | CoI | Strategic Ecosystem Research Partnerships | Leukaemia Foundation | AUD$596,198 |
2019 - 2021 | CIA | Cancer Australia Priority-driven Young Investigator Grant | Cancer Australia/Cure Cancer Australia/Leukaemia Foundation | AUD$198,596 |
2017-2018 | CIA | Cancer Australia Priority-driven Young Investigator Grant | Cure Cancer Australia | AUD$199,454 |
2016 | CIA | Project Grant | Royal Adelaide Hospital Contributing Haematologists' Committee | AUD$25,000 |
2016 | CIE | Project Grant | Royal Adelaide Hospital Research Fund | AUD$50,000 |
Date | Title | Funding Body | Amount |
---|---|---|---|
2018-2021 | Beat Cancer Early Career Cancer Research Fellowship | Cancer Council SA | AUD$240,000 |
2013-2015 | Mary Overton Early Career Fellowship | Royal Adelaide Hospital | AUD$252,000 |
2013-2015 | Veronika Sacco Early Career Fellowship | Florey Medical Research Foundation | AUD$222,003 |
2011 | MMRF Research Fellow Award | Multiple Myeloma Research Foundation (USA) | AUD$74,146 |
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2022 Co-Supervisor Lipidomic and metabolomic profiling of the bone marrow microenvironment to understand multiple myeloma disease development Doctor of Philosophy Doctorate Full Time Miss Mackenzie Rose Skinner 2020 Co-Supervisor Identification of novel mechanisms that drive the dissemination of multiple myeloma tumour cells Doctor of Philosophy Doctorate Full Time Miss Hayley Bridget Parkinson 2020 Principal Supervisor Changes in the bone marrow microenvironment with progression to multiple myeloma Doctor of Philosophy Doctorate Part Time Miss Laura Joy Trainor 2020 Principal Supervisor Development and assessment of novel drug delivery strategies to improve the treatment of multiple myeloma Doctor of Philosophy Doctorate Full Time Ms Sadia Munir 2019 Co-Supervisor The Yin and Yang of Myeloma Development: The Role of the Bone Marrow Microenvironment in Plasma Cell Dormancy and Activation Doctor of Philosophy Doctorate Full Time Miss Natalya Plakhova -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 - 2021 Co-Supervisor Macrophages, Myeloma, Mouse Models and Methodologies Doctor of Philosophy Doctorate Full Time Mrs Khatora Shanae Opperman 2017 - 2020 Principal Supervisor CCR1 as a Therapeutic Target in Multiple Myeloma: Preventing Tumour Dissemination and Therapeutic Resistance Doctor of Philosophy Doctorate Full Time Miss Mara Natasha Zeissig 2013 - 2017 Co-Supervisor The Role of TWIST1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Chee Man Cheong 2012 - 2018 Co-Supervisor N-cadherin: Regulation, Role and Therapeutic Targeting in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mr Krzysztof Mrozik
-
Committee Memberships
Date Role Committee Institution Country 2015 - ongoing Member Women's and Children's Hospital Foundation Research Grants Committee - - 2014 - ongoing Member Australian Society for Medical Research SA Committee - - -
Memberships
Date Role Membership Country 2021 - ongoing Member International Myeloma Society United States 2019 - ongoing Member Australasian Leukaemia and Lymphoma Group Australia 2015 - ongoing - Haematology Society of Australia and New Zealand - 2014 - ongoing Member Australian Society for Medical Research -
Connect With Me
External Profiles